Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | PARG | Q86W56 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | PDE4A | P27815 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | F2RL3 | Q96RI0 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17434526 | 0.95 | PARG (0.59) | CYP1A2PARGKMT2AMAPTMEN1 | |
| SCHEMBL17434506 | 0.93 | CYP1A2 (0.57) | CYP1A2PARGKMT2AMAPTMEN1 | |
| SCHEMBL17434602 | 0.88 | PARG (0.60) | CYP1A2PARGKMT2AMAPTMEN1 | |
| SCHEMBL25425476 | 0.88 | F2RL3 (0.50) | CYP1A2PARGKMT2AMAPTMEN1 | |
| SCHEMBL17434573 | 0.88 | CYP1A2 (0.63) | CYP1A2PARGKMT2AMAPTMEN1 | |
| SCHEMBL17434620 | 0.87 | CYP1A2 (0.73) | CYP1A2PARGKMT2AMAPTMEN1 | |
| SCHEMBL17434270 | 0.85 | CYP1A2 (0.59) | CYP1A2PARGKMT2AMAPTMEN1 | |
| SCHEMBL25422095 | 0.85 | PARG (0.48) | CYP1A2PARGKMT2AMEN1LMNA | |
| SCHEMBL25424268 | 0.84 | PARG (0.47) | CYP1A2PARGKMT2AMEN1LMNA | |
| SCHEMBL25422902 | 0.84 | KMT2A (0.51) | CYP1A2PARGKMT2AMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834520-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-12-05 | — | — | US | disclosed |
| US-20160229814-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-11 | — | — | US | disclosed |
| EP-2975031-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229814-A1 | HETEROCYCLIC COMPOUND | RORB, RORC, RORA | CYP1A2 159/4885PARG 4344/4885KMT2A 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.